Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HOWL | US
-0.06
-2.70%
Healthcare
Biotechnology
30/06/2024
30/08/2024
2.16
2.22
2.27
2.05
Werewolf Therapeutics Inc. a biopharmaceutical company develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company through its proprietary PREDATOR platform designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124 a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330 a conditionally activated Interleukin-12 INDUKINE molecule which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898 a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712 an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics Inc. was incorporated in 2017 and is headquartered in Watertown Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
101.5%1 month
104.9%3 months
113.7%6 months
96.0%-
-
0.91
0.35
0.24
0.57
1.81
-
-56.51M
94.40M
94.40M
-
-1.66K
-
-85.90
-48.27
5.18
4.14
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.73
Range1M
1.04
Range3M
4.07
Rel. volume
0.75
Price X volume
326.11K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Dermira Inc | DERM | Biotechnology | 4.98 | 103.22M | -4.41% | 38.31 | 201.92% |
Seer Inc. | SEER | Biotechnology | 1.68 | 103.20M | -1.75% | n/a | 7.43% |
Assembly Biosciences Inc | ASMB | Biotechnology | 16.26 | 103.18M | 1.06% | n/a | 5.03% |
Citius Pharmaceuticals Inc | CTXR | Biotechnology | 0.57 | 103.01M | 0.60% | n/a | 0.37% |
CASI Pharmaceuticals Inc | CASI | Biotechnology | 6.59 | 101.89M | 0.76% | n/a | 167.26% |
IVVD | IVVD | Biotechnology | 0.8502 | 101.55M | -3.78% | n/a | 0.00% |
Tiziana Life Sciences PLC | TLSA | Biotechnology | 1 | 101.51M | -7.41% | n/a | 0.00% |
Verastem Inc | VSTM | Biotechnology | 2.5 | 100.61M | 1.63% | n/a | 104.63% |
Verrica Pharmaceuticals Inc | VRCA | Biotechnology | 2.35 | 100.27M | -3.69% | n/a | -348.20% |
IO Biotech Inc. Common Stock | IOBT | Biotechnology | 1.5 | 98.82M | -2.60% | n/a | 2.23% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.57 | 0.97 | Cheaper |
Ent. to Revenue | 1.81 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 0.91 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 113.73 | 76.13 | Riskier |
Debt to Equity | 0.35 | -2.05 | Expensive |
Debt to Assets | 0.24 | 0.25 | Par |
Market Cap | 94.40M | 4.04B | Emerging |